SkyePharma is due a payment of $2 million from US group Sciele Pharma, after US regulators opened the door to all doses of its new formulation of Sular.

Sular is a calcium-channel blocker licensed for the treatment of high blood pressure, and the new version uses SkyePharma’s patented Geomatrix technology, which offers more control over the amount of drug released.

According to the company, its Geomatrix systems allow the production of tablets with “a wide range of predictable and reproducible drug release profiles”, enabling, for example, the simultaneous release of two different drugs, at different rates, from one tablet.

In addition to the $2 million triggered by the US approval, the company also stands to receive low mid single digit royalties on net sales of the new formulation, which is scheduled for launch during the first quarter of this year.